Thus, additional studies will inform on the contribution of platelet-lymphocyte aggregation to disease progression in the Pink1/Parkin dKO rat model and we believe studies to assess platelet-lymphocyte aggregation in PD patients are warranted. This evidence concerns the gene PRKN and Parkinson disease.